-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mesdopetam in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mesdopetam in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesdopetam in Parkinson's Disease Drug Details: Mesdopetam (IRL-790) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mesdopetam in Drug-Induced Dyskinesia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mesdopetam in Drug-Induced Dyskinesia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesdopetam in Drug-Induced Dyskinesia Drug Details: Mesdopetam (IRL-790) is under development for...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyskinesia - Drugs In Development, 2023’, provides an overview of the Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mesdopetam in Psychosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mesdopetam in Psychosis Drug Details: Mesdopetam (IRL-790) is under development for the treatment of L-Dopa...
-
Sector Analysis
Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029
Parkinson’s Disease Market Overview Parkinson’s Disease market size across the 7MM was valued at $3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. The US is the most significant contributor to that revenue mainly due to the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. Parkinson’s Disease Market Outlook, 2019-2029 ($ Billion) To gain more information on the Parkinson’s Disease market forecast, download...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movements. Its symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. However, the disease can be controlled by a healthy lifestyle and medication. The Dyskinesia pipeline market research report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...